Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combo for translational treatment of gastric cancer
NCT04258644Phase 2Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), sponsored by Beijing Friendship Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04258644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258644.